ENTX

Entera Bio Ltd.

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

Entera Bio Ltd. (ENTX) is rated C (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B+); its weakest is Profitability (D+). The rating has held at C for 2 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.5 / 5.0
C
Value
C+
Factor Score 2.5 / 5.0
Growth
D+
Factor Score 1.8 / 5.0
Profitability
D+
Factor Score 1.6 / 5.0
Momentum
B+
Factor Score 3.8 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -5.9
EV / EBITDA -37.1
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M 15.7%
Price Return 12M 3.2%
Catalyst Signal 0.00
Market Cap $564.2M
TTM Revenue $0.0
Price / Sales N/A
ROE -138.9%

Historical Factor Score Progression

Held C for 2 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 C+ (2.5) D+ (1.8) D+ (1.6) B+ (3.8) C+ (2.6) C (2.5)
2026-11-04 C+ (2.5) C- (1.9) D+ (1.6) B+ (3.7) C+ (2.7) C (2.5)
2026-10-28 C+ (2.5) C- (1.9) D+ (1.7) B+ (3.6) C+ (2.7) C (2.4)
2026-10-21 C+ (2.5) D+ (1.8) D+ (1.6) A (4.3) C+ (2.6) C+ (2.6)
2026-10-14 C+ (2.5) D+ (1.8) D+ (1.6) A- (4.1) C+ (2.6) C+ (2.5)
Page 1 of 3